Great Basin Q4 Revenues Rise 51 Percent on C. diff Test Sales | GenomeWeb

NEW YORK (GenomeWeb) – Great Basin today reported a 51 percent jump in its fourth quarter revenues on an increase in sales of the company's Clostridium difficile tests. 

For the three months ended Dec. 31, 2014, the Salt Lake City-based firm posted $445,283 in revenues, up from $295,785 for Q4 a year ago. Sales of its C. diff tests resulted from a bump up in the number of the company's customers, Great Basin said, adding it had 84 customers at the end of Q4. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.